Therapy Areas: Oncology
First Neuroendocrine Tumor Patients Dosed with Therapeutic Intent, According to Viewpoint Molecular Targeting
24 January 2023 - - US-based precision oncology company Viewpoint Molecular Targeting, Inc., developing alpha-particle therapies and complementary diagnostic imaging agents, has undertaken first dosing of two neuroendocrine tumor patients with therapeutic intent, the company said.

VMT-α-NET, which is being developed for the treatment and diagnosis of somatostatin receptor subtype 2 (SSTR2) expressing neuroendocrine tumors, was administered to the patients in early December.

The dosed patients were diagnosed with confirmed-advanced somatostatin expressing neuroendocrine tumors.

The administration of VMT-α-NET was under the supervision of the patients' doctor, Dr. Ishida Sen MBBS, director and Head of Nuclear Medicine at Fortis Hospital, New Delhi, in partnership with BJ Madan, a diagnostic & therapeutic radiopharmaceutical company in New Delhi.

No acute adverse reactions were observed in the first 10 days post administration and patients remain stable and in good condition.

Under compassionate use circumstances, VMT-α-NET may be made available to qualified doctors in some countries. In this circumstance, Viewpoint supplied drug precursors and isotopes for the local production of its proprietary radiotherapeutic, VMT-α-NET.

The progress of these patients will be followed by Dr. Sen and her team over the coming months.

The safety and effectiveness of the treatments will be evaluated by Dr. Sen's team with laboratory testing, observation of NET-associated symptoms, and repeat medical imaging.

In the US, VMT-α-NET will imminently enter a Phase 1 imaging and therapy study, to be conducted at various hospitals and clinics.

VMT-α-NET, is categorized as an investigational new drug by the US Food and Drug Association and the administration of VMT-α-NET for compassionate use is completely independent from and not within the scope of the company's Phase 1 trial.

Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents.

The company's proprietary technology utilizes the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides.

Viewpoint is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes.